Granulomas are found in both latent and active forms of TB (
27). However, the immunological differences between a “functional” granuloma that limits infection during L-TB and one that is incapable of controlling infection during A-TB is not clear (
27). Consistent with previous studies, we show that lymphocytic aggregates associated with TB granulomas in mice (
18), NHPs (
4), and humans (
3,
7) exhibit markers associated with ectopic lymphoid tissues, including proliferating GC B cells, CXCR5
+ T cells, and FDC networks, and colocalize with macrophages. Importantly, our experiments in NHPs show for the first time that the formation of organized ectopic lymphoid tissues containing CXCR5
+ T cells within granulomas is associated with better protective outcomes during L-TB, while disorganized lymphoid aggregates coinciding with poor CXCR5
+ T cell localization are associated with poor protective outcomes, as in A-TB. Furthermore, our mechanistic studies with mice show that CD4
+CXCR5
+ T cells exhibit characteristics of Tfh-like cells, while simultaneously expressing markers of Th1 cells. Our data suggest that activated cytokine-producing CD4
+ T cells express CXCR5 as a means to instruct correct localization of Tfh-like cells within the lung parenchyma to activate infected macrophages for optimal control of
Mtb. Our data also demonstrate that a consequence of proper T cell localization within the lung is formation of ectopic lymphoid structures that serve as a useful correlate of protection, but that B cell follicle formation by itself is not protective in the mouse model of TB. Thus, our results have far-reaching implications for the future design of vaccines and therapies to prevent and treat TB.
Our studies using
Cxcr5–/– mice demonstrate that expression of CXCR5 is required for T cell localization within the lung and macrophage activation for
Mtb control.
Cxcr5–/– mice lack mediastinal lymph nodes and exhibit defective splenic architecture (
33) but, following
Mtb infection, generate comparable numbers of antigen-specific cytokine-producing CD4
+ T cells in the lymphoid organs and accumulate in the lung. These data are consistent with previous work (
10) showing that immunization of host mice with antigen in adjuvant resulted in similar expression of ICOS, CD40L, IFN-γ, and IL-4 in adoptively transferred CXCR5-deficient T cells compared with wild-type T cells. Similarly, CXCR5 expression was not required for the expression of Tfh-like markers ICOS and PD-1, production of proinflammatory cytokines, or expression of the Th1 markers Tbet and CXCR3 (data not shown) in CD4
+ T cells in our model. This is also consistent with the findings in mice lacking SLOs, which are still able to control
Mtb infection and induce effective adaptive T cell responses that presumably prime in the lung (
20). That similar numbers of lung myeloid cells accumulate in
Cxcr5–/–
Mtb-infected lungs but exhibit reduced activation suggests that absence of CXCR5-mediated T cell localization within the lung results in impaired ability to activate myeloid cells to control intracellular
Mtb replication. Importantly, we show that adoptive transfer of ESAT-6 Tg T cells or wild-type CD4
+ T cells that can express CXCR5 into
Mtb-infected
Cxcr5–/– mice allows T cells to localize within the lung, activate macrophages, reverse generation of ectopic lymphoid structures, and confer protection against
Mtb infection. These data demonstrate that expression of CXCR5 on T cells is critical for correct T cell localization within the lung parenchyma, likely maximizing macrophage T cell interaction and promoting optimal
Mtb control. Although these studies suggest a direct role for CXCR5 on T cells in CXCL13 responsiveness and T cell localization, it is also possible that CXCR5 expression regulates the expression of additional adhesion molecules or other homing receptors on T cells to impact T cell localization, and this should be further explored. In this context, the ligand for CXCR5, CXCL13, is induced in ectopic lymphoid tissues in response to infection and inflammation (
6,
21,
44). During
Mtb infection, stromal cells, FDCs, and CD11c
+ DCs all produce CXCL13. We show here that CXCL13 expression by non-hematopoietic cells is critical for early production of CXCL13 and immunity, but that both non-hematopoietic and hematopoietic sources of CXCL13 are required for long-term control of
Mtb. Since both stromal cells and FDCs (derived from stromal cells or fibroblasts; refs.
45–
47) express CXCL13 in
Mtb lesions, non-hematopoietic cells likely first respond to infection or infection-induced cytokines, produce CXCL13, and recruit T cells within the lung parenchyma to activate macrophages and facilitate lymphoid structure formation. These data show for the first time that differential cellular sources of CXCL13 in ectopic lymphoid tissues can impact progression of disease and protective outcomes in chronic infections, suggesting that targeting CXCR5/CXCL13 expression may be a powerful tool to improve vaccine strategies and therapy against TB.
In vitro generated Tfh cells are thought to express different cytokines compared with either Th1 or Th2 cells (
36), but in vivo generated Tfh-like cells can express Th1 (
48,
49), Th2 (
48–
51), or Th17 cytokines (
35) in SLOs. Immunization with a protein antigen in adjuvant (
48) or infection with
Leishmania major (
49) and
Toxoplasma gondii (
52) induces IFN-γ production in Tfh-like cells, and B cells isolated from the Tfh-B cell conjugates showed evidence of IFN-γ–induced class switch toward IgG2a (
49). In contrast, IL-4–producing Tfh-like cells are found following infection with
Schistosoma mansoni (
51) or
Heligmosomoides polygyrus (
50) — both models that induce classic Th2 responses. However, recent studies show that Tfh cells are plastic (
53) and that Th1 cells and Tfh-like cells share a transitional stage, during which expression of both Th1 and Tfh cell markers occurs (
52). Our data support this model, as during
Mtb infection, CD4
+ T cells co-exhibit markers expressed by both Tfh and Th1 cells and utilize the characteristics of both these T helper subsets to mediate protective immunity against
Mtb infection. For example, production of proinflammatory cytokines by T cells is crucial for protective immunity against TB in both humans and mice (
22), and studies indicate that expression of multiple proinflammatory cytokines by CD4
+ T cells may provide maximal control of
Mtb infection (
54). This is consistent with our study, where we found that activated CD4
+CXCR5
+ cells that accumulate in the
Mtb-infected lung are the most potent producers of multiple proinflammatory cytokines. In addition, the presence of CXCR3 and/or CXCR5 on activated CD4
+ T cells suggests that T cell responsiveness to multiple chemokines may benefit the host. It is possible that activated CD4
+ T cells express CXCR3 and accumulate in the inflamed lung in response to CXCR3 ligands, then downregulate CXCR3 and upregulate expression of both CXCR5 and proinflammatory cytokines to respond to infection-induced CXCL13 for localization near infected macrophages for
Mtb control. Consistent with this hypothesis,
Cxcr3–/– mice are not more susceptible to low-dose
Mtb infection, despite having defects in early neutrophil recruitment and granuloma formation (
32). In addition, mice lacking other chemokine receptors, such as CCR5 (
55), CCR2 (
56), and CCR7 (
18), are not more susceptible to low-dose
Mtb infection, while absence of CXCR5 or CXCL13 (
19) results in increased susceptibility to TB. These data together suggest that while some chemokine receptor ligands are redundant, the CXCR5/CXCL13 axis plays a unique and non-redundant function in orienting activated proinflammatory cytokine-producing CD4
+ T cells near activated macrophages to mediate protective immunity to TB.
The role for B cells and humoral immunity in protection against
Mtb infection is an emerging area of research, as some components of the humoral immune response such as Fc receptors (
57) have been shown to impact immune responses to TB. Importantly, B cell follicles containing proliferating B cells have been found to colocalize with T cells within human TB granulomas (
3,
7), A-TB in NHPs (
4), and
Mtb-infected mouse granulomas (
18,
19). Surprisingly, B cell–deficient mice are not more susceptible in a physiologically relevant low-dose aerosol
Mtb infection model in published studies (
29,
30), as well as in this study. In addition, our data show that although
Mtb-infected B cell–deficient mice do not form obvious ectopic lymphoid structures, they accumulate CXCR5
+ CD4
+ T cells capable of producing proinflammatory cytokines in the lung and localize within the lung parenchyma for macrophage activation and
Mtb control. This is further supported by our adoptive transfer studies, where WT CD4
+ T cells, but not
Cxcr5–/– CD4
+ T cells, upon transfer into
Cxcr5–/–
Mtb-infected mice can rescue T cell localization within the lung, macrophage activation, and
Mtb control and facilitate B cell follicle formation. These data together suggest that formation of B cell follicles within ectopic lymphoid structures is a consequence of correct T cell localization within the lung and can be effectively used as a correlate of protection against
Mtb infection, but itself may not be necessary for
Mtb control. The potential protective role of B cell follicles in immunity to
Mtb infection in humans is a challenging but crucial question that needs to addressed in future mechanistic studies.
In summary, we show that activated CD4+CXCR5+ T cells accumulate in the Mtb-infected lung, express markers of both Th1-like and Tfh-like cells, respond to infection-induced CXCL13, and strategically localize within the lung parenchyma, activating macrophages and accelerating control of Mtb and forming ectopic lymphoid structures. These results show a novel and previously undescribed role for CD4+CXCR5+ Th cells in the orchestration of protective immunity via macrophage activation. These properties of CD4+CXCR5+ T cells could therefore be exploited to mediate more localized immunity and protection against intracellular pathogens such as Mtb and targeted to improve vaccine strategies against pulmonary pathogens.